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Summary A large-scale prospective study was conducted in 3810 Japanese elderly
(X65 years old) patients with asthma or chronic obstructive pulmonary disease
(COPD) who had been treated with sustained-release theophylline tablets
(THEODURs) at a dose of 400mg/day for 1–6 months, in principle.
Among 3798 protocol-complying patients (mean age: 73.870.10 years, 1997 with
COPD), 261 theophylline-related adverse events were observed in 179 (4.71%)
patients. The 5 most frequently observed adverse events were ‘‘nausea’’ (40
episodes, 1.05%), ‘‘loss of appetite’’ (22 episodes, 0.56%), ‘‘hyperuricemia’’ (16
episodes, 0.42%), ‘‘palpitation’’ (15 episodes, 0.39%), and ‘‘increased alkaline
phosphatase’’ (11 episodes, 0.28%). No convulsions were reported. Six patients had
serious adverse events.
The incidence of theophylline-related adverse events was higher in patients with
hepatic disease (odds ratio: 1:1.81) and in patients with arrhythmia (odds ratio:
1:1.88). Blood drug concentration measurements in 736 patients indicated that the
drug levels were p15 mg/ml in 641 patients (87.1%), and no correlation was noted
between dose and theophylline-related adverse events.
These results suggest that sustained-release theophylline can be used safely in
elderly patients with asthma or COPD.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Theophylline has been used for many years for the
treatment of asthma and chronic obstructive
pulmonary disease (COPD). The control of blood
theophylline concentrations has become easier
since the development of sustained-release pre-
parations. In addition, the anti-inflammatory effect
of theophylline has also been documented.1–4
Sustained-release theophylline plays an important
role in the pharmacotherapy for asthma and COPD.
The toxic range of blood theophylline concentra-
tions is generally considered to exceed 15 mg/ml.5
Following oral administration of sustained-release
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theophylline at the usual dose (in Japan, 400mg/
day), blood theophylline concentrations in excess
of 15 mg/ml and theophylline-related adverse
events are rarely observed. Most serious adverse
events of theophylline have been observed when
the drug was overdosed.5 However, adverse events
of theophylline may develop also in patients
who are taking the usual dose because the
clearance of theophylline is modified by various
factors, including aging,6–13 a reduction in physio-
logical hepatic function14–20 and drug interactions
with other medications.21,22 To investigate the
incidence and severity of such adverse events, we
studied elderly patients who received sustained-
release theophylline in the present large-scale
prospective study.
Patients and methods
Japanese elderly (X65 years old) with bronchial
asthma (BA) or chronic obstructive pulmonary
disease (COPD), who received sustained-release
theophylline (THEODURs 100- or 200-mg Tablets,
Nikken-Chemicals, Tokyo, Japan) between January
1, 1999 and March 31, 2000, were registered in
order of their visits as subjects according to the
continuous entry method.
Patients with a history of serious adverse
events caused by xanthine-derived drugs were
excluded.
A serious adverse event was defined to be any
untoward medical occurrence that at any dose:
* results in death,
* is life-threatening,
* requires inpatient hospitalization or prolonga-
tion of existing hospitalization,
* results in persistent or significant disability/
incapacity,
* is a congenital anomaly/birth defect, or
* does not meet any of the above criteria for
seriousness but may jeopardize the patient or
subject or may require medical or surgical
intervention to prevent one of the outcomes
listed above.
As a general rule, the daily dose was 400mg for
sustained-release theophylline which was adminis-
tered orally twice a day in the morning and at night
in accordance with the approved regimen in Japan.
However, the dose was adjusted according to the
patient’s status. Adverse events which developed
during the study period of 4 weeks or longer were
recorded. Patients were examined up to 6 months
after the onset of the present study.
The date of and reason for discontinuation or
withdrawal from the present study were recorded,
if any, and the clinical course of the relevant
patients was monitored when conductible. All
adverse events reported during the study period
were recorded. Regarding all observed adverse
events, the date, symptoms, severity, drugs other
than theophylline and outcomes were recorded.
Causality of an adverse event with theophylline was
categorized as follows: (1) related; (2) probably
related; (3) probably unrelated; and (4) undeter-
minable. The severity of an adverse event was
categorized as follows: (1) died; (2) injured; (3)
potential risk of death or injury; (4) hospitalized for
treatment or increased the hospitalization period;
(5) severe; (6) moderate; and (7) mild. Categoriza-
tion was made by the attending physician. Serious
adverse events were defined as those which were
categorized to 1–5.
Blood theophylline concentration at the time
of adverse event development was also recorded
when conductible. This study was conducted
in compliance with the Good Post-Marketing
Surveillance Practice which had been imple-
mented by the Ministry of Health and Welfare in
April 1994.
Bonferroni–Dunn’s test was performed for para-
metric data, whilst w2 test was performed for
nonparametric data, both at a P-value of 0.05, two-
tailed.
Results
Subjects
The present study included a total of 3810 patients.
However, 12 patients were excluded from the
present study due to protocol violation. Therefore,
3798 patients (mean age: 73.8 years) remained as
patients who were eligible for the analysis of safety
(Table 1).
Among 3798 patients, 2720 showed one or more
concurrent diseases which totaled to 5690 in
number, 2227 of which were related to the
cardiovascular system and 184 to the liver system.
The present study was terminated within 4 weeks
after the onset of the present study in 148 patients
(3.90%). The most frequent causes were as follows:
failures to visit the hospital after previous visit(s)
and to follow-up the patient in 52 patients (1.37%);
adverse events in 30 patients (0.79%); improvement
of symptoms in 16 patients (0.42%); and develop-
ment or aggravation of complications in 15 patients
(0.39%).
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Table 1 Patient background factors.
Gender Male 2568 67.6%
Female 1230 32.4%
Body weight (kg) Mean7SE; 53.870.18 (range: 24.5–90.0)
Theophylline dose (mg) Mean7SE; 34271.86 (range:100–900)
Age Mean7SE; 73.870.10 (range: 65–95)
65–74 2213 58.2%
75–84 1381 36.4%
85– 204 5.4%
Diagnosis CB and/or emphysema 1999 52.6%
Bronchial asthma 1728 45.5%
Bronchial asthma and others 19 0.5%
Bronchiectasis 14 0.4%
Diffuse panbronchiolitis 8 0.2%
Pulmonary fibrosis 4 0.1%
Interstitial pneumonia 3 0.1%
Pneumoconiosis 3 0.1%
Others 14 3.7%
No description 1 0.03%
Severity of Subject diseasen Mild 1432 37.7%
Moderate 1896 49.9%
Severe 466 12.3%
No description 4 0.1%
Concurrent diseasew Present 2720 71.6%
Circulatory disease 1284 33.8%
Hypertension 1273 33.5%
Cardiac disease 943 24.8%
Angina pectoris 345 9.1%
Arrhythmia 288 7.6%
Heart failure 209 5.5%
Gastrointestinal disease 837 22.0%
Gastric ulcer 226 6.0%
Gastritis 202 5.3%
Metabolic disease 830 21.8%
Diabetes mellitus 321 8.5%
Hyperlipidemia 274 7.2%
Hyperuricemia 207 5.5%
Pulmonary disease 477 12.6%
Central nervous disease 461 12.1%
Urinary disease 213 5.6%
Hepatic disease 184 4.8%
Absent 1067 28.1%
No description 11 0.3%
History of smoking Present 1788 47.0%
Absent 1525 40.2%
No description 485 12.8%
nPhysician’s determination.
wConcurrent diseases observed in more than 200 patients are listed in the categories by organ. No complications, including
pulmonary disorders, were found in more than 200 patients.
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Incidence of adverse events
Among 3798 patients, 327 were reported to have
developed adverse events (Table 2), including 261
adverse events of theophylline in 179 patients
(4.71%).
Gastrointestinal disorders (110 episodes, 2.90%)
including nausea (40 episodes, 1.05%) were re-
ported most frequently, followed by metabolic
disorders (44 episodes, 1.16%) including hyperur-
icemia (16 episodes, 0.42%) and increased LDH (8
episodes, 0.21%). There were 15 episodes of
palpitation (0.39%). No convulsions were reported.
Factors which affect adverse events
Differences in the incidences of adverse events of
theophylline were analyzed according to demo-
graphic factors (Fig. 1). Patients with liver dis-
orders and patients with concomitant arrhythmia
more frequently showed adverse events of theo-
phylline, with odds ratios of 1:1.81 (P¼ 0.005) and
1:1.88 (P¼ 0.030), respectively.
There was no correlation between the incidence
of theophylline-related adverse events and the
severity of patient’s concurrent disease. Neither
was found a correlation between the dose of
theophylline and the severity of concurrent dis-
ease.
The effects of concurrent drugs were examined.
Consequently, no significant difference was found
in the risk ratio of theophylline-related adverse
events according to the presence or absence of
concurrent drugs. Furthermore, the effects of
concurrent drugs were examined according to their
categories, i.e., beta-receptor agonists, inhaled
steroids, anticholinergics, and antibiotics. Accord-
ingly, no significant difference was found in the risk
ratio of theophylline-related adverse events ac-
cording to the presence or absence of concurrent
drugs. In addition, beta-receptor agonists were
concurrently used by as many as 39% of patients.
Therefore, the odds ratios of theophylline-related
adverse events were compared between the beta-
receptor agonist combination group and the beta-
receptor agonist noncombination group according
to the categories of adverse events (palpitation,
tachycardia, arrhythmia, headache, insomnia, cen-
tral nervous system (CNS) disorders and cardiovas-
cular system (CVS) disorders). Consequently, no
significant difference was found.
There is a report which has described changes in
theophylline clearance after smoking cessation.23
Therefore, the incidences of theophylline-related
adverse events were compared among different
groups according to the period from the onset of
smoking cessation to the onset of the present study
with respect to patients who had a past history of
smoking (currently no smoking)’’Fwhich derived
from consideration that they ceased smoking prior
to the present study. Consequently, no significant
difference was found (Fig. 1).
Theophylline-related adverse events observed
showed no correlation with age (Table 3).
There was no correlation between the severity of
subject disease and the incidence of theophylline-
related adverse events. Neither was found a
correlation between the dose of theophylline
and the severity of subject disease (3-category
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Table 2 Incidences of theophylline-related adverse events (n¼ 3798).
Number of adverse
reactions
(%)
Patients with adverse events 327
Patients with theophylline-related adverse eventsn 179 4.71
Number of episodes of theophylline-related adverse eventsn 261
Gastrointestinal disorders (nausea (40), loss of appetite (22)) 110 2.90
Metabolic nutritional disorders (hyperuricemia/elevated blood uric
acid level (16), increased Al-P (11))
44 1.16
Cardiovascular disorders (palpitation (15), tachycardia (3)) 28 0.74
Central nervous system disorders (insomnia (7), headache (5)) 28 0.74
Urinary disorders (proteinuria (7), increased BUN (2)) 14 0.37
Hepatic and biliary disorders (increased AST (7) and ALT levels (5)) 12 0.32
Hematologic disorders (leukocytopenia (3), erythrocytopenia (2)) 11 0.29
Othersn (itching, thoracic discomfort/chest pain) 14 0.37
These diseases were categorized in accordance with Adverse Drug Reaction Terminology (supervised by Safety Division,
Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, 1996).
nPhysician’s determination.
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criterion: (1) mild; (2) moderate; and (3) severe).
There was great bias as manifested by doses which
were found principally within a range of 200–
500mg regardless of the severity of subject disease
(Table 4). No significant difference was found
according to severity.
Blood theophylline concentration
Blood theophylline concentrations were measured
in 736 patients at 1049 time points. The maximum
blood theophylline concentration in individual
patients was p15 mg/ml in 641 patients (87.1%).
Although a positive correlation was observed
between daily dose and blood theophylline con-
centration, no correlation was observed between
blood drug concentration or daily dose and the
incidence of theophylline-related adverse events.
(Fig. 2, Table 3). Blood theophylline concentrations
did not increase in patients with concurrent liver
disease.
Serious adverse events
Six of 3798 patients (Table 5) reported serious
theophylline-related adverse events, 4 of which
were related to the cardiovascular system. One
serious adverse event, which was categorized to
‘‘probably related’’ in causality, was ventricular
tachycardia which recovered in terms of outcome.
Among patients in whom blood theophylline
concentrations were measured and who developed
adverse events of theophylline, 8 showed drug
blood concentrations in excess of 20 mg/ml. Seven
and one of these 8 patients developed theophyl-
line-related adverse events which were related
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*p < 0.05 (χ2 test)
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Figure 1 The risk ratios of concurrent disease for adverse events of theophylline are shown. The incidences of adverse
events of theophylline were significantly higher in patients with hepatic disease or arrhythmia. Smoking history 1:
patients who had ceased smoking within one year before the study onset. Smoking history 2: patients who had ceased
smoking within one month before the study onset.
Table 3 Incidences of theophylline-related ad-
verse events in patients categorized by age and by
daily dose.
N Incidence of
adverse
events (%)
w2 test
Age (years)
65–74 2213 4.84 ns
75–84 1381 4.49
85– 204 4.90
Daily dosen (mg)
100–200 1097 4.28 ns
300–400 2467 5.07
500–600 205 3.41
700–800 27 0.00
Two patients received theophylline at 800mg/day or
higher doses, and theophylline-related adverse events
were observed in one of them.
nAdverse reactions ‘‘present’’: daily dose at the time of
onset. Adverse reactions ‘‘absent’’: the maximum daily
dose per patient.
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with the GI system and increased alkaline phospha-
tase, respectively (Table 6).
Discussion
There are many randomized controlled trials which
show the efficacy of theophylline for the treatment
of asthma and COPD. Mechanisms of action of
theophylline include bronchodilation and anti-
inflammatory activity.1–4 In the past, the therapeu-
tic blood level of theophylline was considered to be
5–20 mg/ml at steady state. In recent years,
however, the target blood level of theophylline in
a more cautious regimen is considered to be 5–
15 mg/ml.5 Bronchodilation is more intense when
blood theophylline concentrations exceed 10 mg/ml
as compared with lower ranges, whilst its anti-
inflammatory activity is observed from 5 mg/ml. A
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Figure 2 The daily dose correlated with blood theophylline concentrations. The circles represent blood drug
concentrations in patients who developed no adverse events of theophylline, and the squares represent blood drug
concentrations in patients who developed adverse events of theophylline. Blood theophylline concentrations were not
correlated with the incidence of adverse events when analyzed at each dose.
Table 4 Incidences of theophylline-related adverse events and mean daily doses in patients who were
categorized by severity of subject disease.
Severity n Incidence of
adverse events (%)
w2 test Mean daily dose
(mg)
w2 test
BA
Severe 118 4.2 ns 382.1787.2 ns
Moderate 796 4.6 370.3785.3
Mild 812 4.4 331.3799.6
Total 1728 4.5 F 352.7794.6 F
COPD
Severe 339 3.2 ns 334.7795.9 ns
Moderate 1062 4.4 335.7791.3
Mild 596 6.5 316.27108.7
Total 1999 4.9 F 329.77109.9 F
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recent report24 provided a good explanation about
the mechanism by which theophylline exerts its
anti-inflammatory activity, i.e., regulation of his-
tone deacetylase. Blood theophylline concentra-
tions in excess of 20mcg/ml may provoke serious
adverse events, and blood drug concentrations in
excess of 30 mg/ml may even more frequently
provoke adverse events, e.g., arrhythmia and
convulsions.
Elderly patients may present decreased liver
function and have a higher incidence of adverse
events which are associated with pharmacotherapy.
Therefore, the safety of all drugs used in pharma-
cotherapy should be carefully studied in this
population. There is a report which has described
a correlation between theophylline-related ad-
verse events and age.25 However, there have been
few studies on the safety of theophylline which
focused on elderly patients. We conducted the
present prospective, large-scale study to examine
the safety of sustained-release theophylline in 3810
Japanese elderly patients with asthma and COPD.
The mean age of patients was 73.8 years, with
more than 40% being over age X75. More than 70%
of patients received concurrent drugs; 2200 of
them received concurrent drugs which were re-
lated to the cardiovascular system.
The recommended daily dose of theophylline in
the present study is 400mg in accordance with the
approved dose in Japan and corresponds to
approximately 7.4mg/kg/day. Concurrent drugs,
e.g., anticholinergic drugs (18.7%), b2-receptor
agonists (39.2%), and inhaled corticosteroids
(35.0%), were also employed. Although the efficacy
of these concurrent drugs was not assessed in the
present study, the rate of discontinuations due to
the causes other than improvement of symptoms
was only 3.5% (132/3798).
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Table 5 Listing of serious theophylline-related adverse events.
Patient’s
initial
Gender Age
(years)
Body weight
(kg)
Dosage
(mg)
Adverse
events
Causality with
theophylline
Outcome Blood
theophylline
concentration
KM Female 71 73 200 b.i.d Ventricular
tachycardia
Probably
related
Recovered No data
KS Male 73 51 200 b.i.d Atrial fibrillation
[paroxysmal]
Probably
unrelated
Recovered No data
100 b.i.d. Atrial fibrillation
[paroxysmal]
Probably
unrelated
Recovered No data
TM Male 70 89 200 b.i.d Aggravation of
hypertension
Probably
unrelated
Recovered No data
YM Male 68 50 200 b.i.d Mallory–Weiss
syndrome
Probably
unrelated
Recovered No data
SY Male 89 Unknown 100 t.i.d. Aggravation of
gastric ulcer
Undetermined Failure to
follow-up
12.4mcg/ml
MH Male 78 50 300 t.i.d. Status
asthmatics
Undetermined Death No data
Arrhythmia Undetermined No data
Serious adverse events were reported in 6 of 3798 patients (8 episodes).
Table 6 Theophylline-related adverse events at concentrations over 20mcg/ml.
Patient no. Daily dose
(mg)
Blood theophylline
concentration (mg/ml)
Adverse event
1 400 20.09 Anorexia
2 600 20.20 Anorexia
3 400 20.70 Nausea, anorexia
4 400 21.00 Nausea
5 400 21.10 Diarrhea, abdominal distension,
insomnia
6 400 23.70 Increased Al-P
7 400 26.80 Nausea
8 400 32.10 Nausea
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In parallel with the present safety study, we
conducted a pharmacokinetic study of theophylline
between the elderly group (n¼ 16, mean age: 68.9
years) and the young healthy volunteer group
(n¼ 16, mean age: 26.6 years). The Cmax and AUC
showed significant increases in the elderly; how-
ever, respective differences of 18% and 20%
between the two groups in terms of these pharma-
cokinetic parameters were not considered to be
clinically significant.26
In the present large-scale study, the incidence of
the theophylline-related adverse events was less
than 5%. It is difficult to compare this incidence
with the values reported in other studies which
were conducted in general populations because the
present study is not designed as a double-blind
study. The conduct of a double-blind study with
reference drugs, e.g., theophylline, is considered
inappropriate in Japan. Serious theophylline-re-
lated adverse events were observed in 6 patients
(0.2%); one of them, tachycardia, was categorized
to ‘‘probably related’’ in causality, whilst the others
were categorized to either ‘‘probably unrelated’’ or
‘‘undeterminable’’ in causality. No convulsions
were reported. The incidence of theophylline-
related adverse events which required hospitaliza-
tion has been reported to be 7.8 patients per
10,000 patients,27 whilst the result of the present
study indicated 6 patients per 3798 patients.
No significant difference was found in the
incidence of theophylline-related adverse events
according to the use of concurrent drugs, e.g.,
anticholinergic agents, b2-receptor agonists and
inhaled corticosteroids. Concurrent use of these
therapeutic drugs for asthma and COPD with
theophylline suggested not to affect risks of
developing theophylline-related adverse events.
There was no correlation between the severity of
subject disease and the incidence of theophylline-
related adverse events. Neither was found a
correlation between the dose of theophylline and
the severity of subject disease. One admissible
reason for no correlation between the severity of
subject disease and doses is that there are great
differences in theophylline clearance from one
patient to another. In consideration of this fact,
emphasis is given in maintaining blood theophylline
concentrations at doses which are appropriate for
individual patients.
The adverse events associated with theophylline
therapy that were observed in the present study
were not related to age. Higher blood theophylline
concentrations in the elderly had been reported.
Therefore, we predicted that the incidence of
theophylline-related adverse events would increase
with age. However, the results of the present study
were contrary to our prediction. The report that
blood theophylline concentrations are higher in the
elderly than in the young derived from studies
which incorporated 2 groups, i.e., one of the young
and another of the elderly. However, little study is
available in which the elderly only was examined
like ours. A study which examined the relationship
between age and clearance in the Japanese
population has reported that drug clearance
decreases but gradually with age in the elderly
X60 years of age (66–70 years: 38.5712.2ml/kg/
h; 71–75 years: 35.6712.4ml/kg/h; 76–80 years:
35.7710.3ml/kg/h; and 81Xyears: 33.8712.9ml/
kg/h).9 Blood theophylline concentrations were
calculated based on these mean values, assuming
that theophylline 400mg/kg/day is administered to
patients 50 kg of body weight in respective layer of
age. Consequently, the following values were
calculated: 66–70 years, 8.66 mg/ml; 71–75 years,
9.36 mg/ml; 76–80 years; 9.34 mg/ml; 81Xyears,
9.86 mg/ml. These results lead us to conjecture that
changes in blood theophylline concentrations due
to age-induced changes in clearance are generally
small in the case of using theophylline at a low dose
like the present study and to consider that such
small changes did not provoke differences in the
incidence of theophylline-related adverse events
according to the layers of age. As indicated by the
results of comparison of theophylline pharmacoki-
netics between the elderly and the nonelderly in
another study which we conducted, furthermore,
we consider that differences in blood theophylline
concentration according to age are not necessarily
large. However, further study is required to
examine what is the extent of changes due to
aging in patients with the factors which modify
theophylline clearance, e.g., hepatic disease.
In addition, reports that the incidence of
theophylline-related adverse events increases
dose-dependently are prevailing. However, the
present study revealed no correlation between
blood theophylline concentrations and the inci-
dence of theophylline-related adverse events. One
admissible explanation for this result is that blood
theophylline concentrations were concentratedly
found at relatively low levels. Blood theophylline
concentrations which were successfully measured
in the present study were in the nontoxic range,
i.e., p15 mg/ml, in the majority (87.1%) of
patients. Conventional reports on the correlation
between blood theophylline concentration and its
adverse events have described wide ranges of blood
drug concentrations and have included many
patients whose blood theophylline concentrations
exceeded 15 mg/ml. In a study which includes many
patients whose blood theophylline concentrations
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are in the nontoxic range like the present study, it
is admissible to consider that a definite correlation
between blood theophylline concentrations and its
adverse events is not necessarily found. Adverse
reactionsFwhich are not correlated with blood
theophylline concentrations despite they are in the
therapeutic rangeFdeveloped, and these adverse
reactions are termed caffeine-like adverse reac-
tions.28–30 In that case, mild adverse reactions in
the gastrointestinal system, e.g., nausea, and in
the psychiatric and nervous systems, headache and
insomnia, are considered to form the mainstay. The
majority of theophylline-related adverse events
which were observed in the present study were
similar to the abovementioned ones and are there-
fore considered to be caffeine-like adverse events
which are correlated with blood theophylline
concentrations.
Theophylline-related adverse events were fre-
quently observed in patients with hepatic disease
and arrhythmia, suggesting the need for a cautious
approach in these patients. This result is consistent
with the reports that theophylline clearance
decreases due to hepatic disease.14–18
In conclusion, low-dose sustained-release theo-
phylline can be used with acceptable safety in most
elderly patients with asthma and COPD.
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